Antiproliferative Activity of Double Point Modified Analogs of 1,25-Dihydroxyvitamin D₂ Against Human Malignant Melanoma Cell Lines

Anna Piotrowska 1, Justyna Wierzbicka 1, Sharmin Nadkarni 2, Geoffrey Brown 3, Andrzej Kutner 2 and Michał A. Żmijewski 1,*

Received: 27 November 2015; Accepted: 21 December 2015; Published: 8 January 2016

Abstract: Vitamin D is a lipid soluble steroid hormone with pleiotropic biological properties, including regulation of cell proliferation, differentiation and apoptosis. As to these desirable anticancer actions, 1,25-dihydroxyvitamins D and analogs have been reported to inhibit the proliferation and to induce differentiation of a wide variety of cancer cell types, including human malignant melanoma. However, there is a need for novel and more efficacious vitamin D analogs, and how best to design such is still an open issue. A series of double point modified (DPM) analogs of 1,25-dihydroxyvitamin D₂ (1,25(OH)₂D₂) induced differentiation of the vitamin D receptor (VDR) positive A375 and VDR negative SK-MEL 188b human malignant melanoma cell lines. Surprisingly, the dose of 1,25(OH)₂D₂ required to inhibit the proliferation of the A375 melanoma cell line by was several fold lower than that required in the case of 1,25(OH)₂D₃. To evaluate the impact of the modification in the side chain (additional 22-hydroxyl) and in the A-ring (5,6-trans modification), the regular side-chain of vitamin D₂ or D₃ was retained in the structure of our analogs. As expected, 5,6-trans modification was advantageous to enhancing the anti-proliferative activity of analogs, but not as a single point modification (SPM). Very unexpectedly, the additional 22-hydroxyl in the side-chain reduced significantly the anti-proliferative activity of both the natural and 5,6-trans series analogs. Finally, an induction of pigmentation in melanoma SK-MEL 188b cells was observed to sensitized cells to the effect of vitamin D analogs.

Keywords: vitamin D; vitamin D₂; novel vitamin D analogs; melanoma; skin cancer; VDR

1. Introduction

Vitamin D is perhaps the oldest existing hormone [1,2]. As early as 750 million years ago, phytoplankton and zooplankton produced vitamin D in the oceans [2]. There are two forms of vitamin D—ergocalciferol (D₂) and cholecalciferol (D₃) [3], which differ from each other in a Δ²² double bond and a methyl in the side chain at C-24 in vitamin D₂ (Figure 1) [4].

Simple life forms, like krill or brine shrimp, contain 7-dehydrocholesterol (7-DHC) as well as ergosterol, the precursors for vitamin D₃ and D₂, respectively [1]. Vitamin D₃ is mainly produced in the skin via photolysis of 7-DHC through a two-step process in which the B-ring is broken in a photolytic process driven by ultraviolet B (UVB) irradiation, giving the previtamin D₃ [4]. Previtamin D₃ very
quickly isomerizes to vitamin D₃ in a thermal non-catalytic process [4]. By contrast, vitamin D₂ is synthesized in plants and fungi from UVB-irradiated ergosterol [4].

![Structures of 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) and 1,25-dihydroxyvitamin D₂ (1,25(OH)₂D₂).](image)

It is well established that vitamin D₂ is as effective as vitamin D₃ in maintaining the proper level of the main circulating vitamin D metabolite, which is 25-hydroxyvitamin D (25(OH)D) [5].

Vitamin D is biologically inert and regardless of the source it requires two subsequent steps of hydroxylations to gain activity. The first, at C-25, takes place in the liver and second, at C-1 in an α orientation, in the kidney [6]. The essential and the most widely known role of vitamin D is regulation of calcium homeostasis for bone health [7]. However, the activity of the hormonal form of vitamin D extends far beyond mineral homeostasis and skeletal health maintenance [3]. The widespread expression of vitamin D receptor (VDR) and the enzyme responsible for final activation of 25(OH)D tissues emphasizes the diversity of vitamin D-dependent regulatory mechanisms that are both autocrine and paracrine [1,8–13]. As to function of vitamin D, this can be elicited by genomic and non-genomic mechanisms [14]. By binding to vitamin D response elements (VDRE) in the promoter regions [15–17], 1,25(OH)₂D may regulate at least 3000 genes in the human genome [14]. The non-genomic and rapid response to 1,25(OH)₂D relies on signal transduction pathways leading to modulation of the intracellular concentration of calcium [2,14].

Regulation of calcium concentration in serum as required for proper bone mineralization is the major function of the hormonal form of vitamin D [7,18]. It should be emphasized, however, that the role of activated cholecalciferol is much more diverse. The non-calcemic effects of vitamin D include regulation of proliferation, differentiation and apoptosis [19–24], and 1,25(OH)₂D is one of the most potent inhibitors of cell growth [25,26]. Therefore, vitamin D analogs are considered as promising anticancer compounds, which is supported by data from preclinical studies and epidemiological that relate low levels of vitamin D to an increased risk of cancer [27–40].

Previously, we have investigated the activities of low calcemic analogs of vitamin D₃ with 20-hydroxyl, as well as analogs with a short side chain ([41,42], also see [40,43] for recent reviews). In our continuous search for more active vitamin D analogs for use as potential therapeutics [44], we have investigated the analogs of 1,25-dihydroxyvitamin D₂ (1,25(OH)₂D₂) [45]. Following the discovery [46] of an ample free space around the terminal part of the side-chain we designed [47], synthesized [48] and investigated the biological activity of side-chain homologated analogs [49]. A favorable activity profile was observed for analogs containing a side chain with an ATRA-like all-trans geometry [50]. However, in order to evaluate the importance of double point modifications (DPM) in the vitamin D molecule, i.e., in the A-ring (5,6-trans) and in the side-chain (22-hydroxyl and 24-epi), we returned our attention to analogs with the regular untouched D₂- or D₃-like side-chain.

In this study, we have investigated the capacity of our series of (DPM) analogs of 1,25-dihydroxyvitamin D₂ to inhibit cell proliferation of the human malignant melanoma VDR positive A375 and VDR depleted SK-MEL 188b cell lines.
2. Results

2.1. New Vitamin D Analogs Effectively Inhibit A375 Cell Proliferation

Figure 2 shows the effect of 1,25(OH)$_2$D$_3$, 1,25(OH)$_2$D$_2$ and the analogs PRI-1730–PRI-1734 on the proliferation of the human melanoma cell line A375. These analogs inhibited the proliferation of A375 melanoma cells, as determined using the Sulphroamin B assay (SRB) (Figure 2A–G). IC$_{50}$ values ranged from 1.5 nM for PRI-1730 to around 0.028 nM, with the highest activity observed for PRI-1733 (Table 1). The effect of the analogs varied as to the level of maximal inhibition of proliferation which ranged from 10%–15% for 1,25(OH)$_2$D$_3$ and 1,25(OH)$_2$D$_2$ to 20%–30% for the new analogs.

Figure 2. The effect of vitamin D analogs on the proliferation of human malignant melanoma A375 cells. The cells were treated with serial dilutions ($10^{-12}$–$10^{-6}$ M) of 1,25(OH)$_2$D$_3$ (A), 1,25(OH)$_2$D$_2$ (B), PRI-1730–PRI-1734 (panels (C–G), respectively) for 24 h. Data are shown as mean from three independent experiments ± S.D. Statistical significance was estimated using One–Way ANOVA and presented as * $p < 0.05$, ** $p < 0.005$, *** $p < 0.0005$ vs. control.
Table 1. Summary of the IC₅₀ values for inhibition of proliferation of the human malignant melanoma A375 cells.

| Compound    | IC₅₀ (nM) |
|-------------|-----------|
| 1,25(OH)₂D₃ | 0.656     |
| 1,25(OH)₂D₂ | 0.036     |
| PRI-1730    | 1.500     |
| PRI-1731    | 0.524     |
| PRI-1732    | 0.053     |
| PRI-1733    | 0.028     |
| PRI-1734    | 0.497     |

2.2. Treatment of A375 Human Malignant Melanoma Cells with the New Vitamin D Analogs Resulted in G₀/G₁ Arrest

To further investigate the inhibition of A375 cell proliferation by the new vitamin D analogs, we analyzed the extent to which analogs affected the distribution of melanoma cells in various phases of the cell cycle by flow cytometry. All the analogs tested, except PRI-1734, increased the percentage of melanoma cells in the G₀/G₁ phase of cell cycle and this was accompanied by proportional decrease in the number of cells in the S and G₂/M phases of cell cycle (Figure 3).

Figure 3. Effect of 24 h incubation with vitamin D analogs at 100 nM concentration on the distribution of human malignant melanoma A375 cells throughout phases of the cell cycle (SubG₁—apoptotic/necrotic cells, G₁—growth, S—DNA synthesis, G₂/M—preparation for mitosis/mitosis). Cells were harvested, stained with propidium iodide and analyzed by Flow Cytometry. Data are presented as mean ± S.D. of three independent experiments carried out in triplicate. *p < 0.05; **p < 0.01 vs. control.

2.3. SK-MEL 188b Melanoma Cells Do Not Express VDR Receptor and Vitamin D 24-Hydroxylase (CYP24A1)

It is well established that inhibition of proliferation and stimulation of differentiation of various cancer cell lines by vitamin D and its analogs requires the expression and activity of VDR. To establish whether the biological activity of the newly synthesized analogs of vitamin D against melanoma cells required the presence of active VDR we tested analogs for activity against the melanoma cell line SK-MEL 188b. SK-MEL 188b is a spontaneous subclone of SK-MEL 188b melanoma that lacks active VDR.
Post-treatment of A375 melanoma with 1,25(OH)_2D_3, expression of VDR was inhibited slightly, while CYP24A1, the vitamin D catabolic enzyme, was strongly induced (Figure 4). Transcripts for VDR and CYP24A1 genes were not detected in SK-MEL188b cells.

Furthermore, incubation of human malignant melanoma SK-MEL 188b cells with active form of vitamin D_3 did not lead to the appearance mRNAs for either VDR or CYP24A1 (Figure 4).

Figure 4. Effects of 1,25(OH)_2D_3 on VRD (A) and CYP24A1 (B) gene expression in A375 and SK-MEL 188b human malignant melanoma cells. mRNA levels were measured by qPCR. Data are shown as means ± S.D of three independent experiments carried out in duplicate. NT—not treated, control cells.

2.4. Inhibition of Melanoma Proliferation by Novel Vitamin D Analogs Is Reliant on VDR

To resolve whether the effect exerted by new vitamin D analogs on A375 cells is dependent on VDR, we tested analogs for activity against SK-MEL 188b human malignant melanoma cells which, as above, lack VDR (see Figure 4).

The new vitamin D analogs had only a very minor influence on non-pigmented SK-MEL 188b melanoma cells (Figure 5). The levels of inhibition observed were not statistically significant for all compounds other than PRI-1631, which gave an IC_{50} value of 0.408 nM. We were not able to calculate valid IC_{50} values for the remaining compounds (Table 2). Furthermore, at most we only observed approximately a 10% decrease in cell viability even at the maximal concentration used of 1 μM. The PRI-1731 analog was the only analog that decreased viability of SK-MEL 188b melanoma cells to a level of approximately 20% (Figure 5D).

Table 2. Summary of IC_{50} values for inhibition of proliferation of non-pigmented human malignant melanoma SK-MEL 188 cells. NS—not significant.
Figure 5. The effect of Vitamin D analogs on the proliferation of the human malignant melanoma SK-MEL 188 cells post-treatment with serial dilutions ($10^{-12}$–$10^{-6}$ M) of $1,25(\text{OH})_2\text{D}_3$ (A), $1,25(\text{OH})_2\text{D}_2$ (B), PRI-1730–PRI-1734 (panels (C–G), respectively) for 24 h. Data shown are the mean from three independent experiments ± S.D. Statistical significance was estimated using One–Way ANOVA and presented as ** $p < 0.005$, *** $p < 0.0005$ vs. control.
2.5. New Vitamin D Analogs Had Only a Very Limited Effect on Non-Pigmented SK-MEL 188b Melanoma Cells as to the Distribution of Cells in Phases of the Cell Cycle. NS—Not Significant

Figure 6 shows that the new vitamin D analogs had very little effect on the distribution of SK-MEL 188b melanoma cells in various phases of the cell cycle. In fact, vitamin D analogs at 100 nM concentration increased the percentage of melanoma cells in S and G2/M and there was a decrease in number of cells in G1 (Figure 6A). This effect is opposite to that provoked by vitamin D analogs in the case of A375 cells, perhaps due to different genetic background (a lack of VDR in SK-MEL 188b) and an activation of alternative pathways (e.g., PDIA-3 rapid response [2,14]). At higher concentrations of analogs (1000 nM) the observed effects against SK-MEL 1288 cells were not statistically significant (Figure 6B).

![Figure 6](image_url)

**Figure 6.** Effect of 24 h incubation with vitamin D analogs at 100 nM (A) and 1000 nM (B) concentration on the distribution of non-pigmented human malignant melanoma SK-MEL 188 cells throughout the phases of cell cycle. Cells were harvested, stained with propidium iodide and analyzed by Flow Cytometry. Data are the mean ± S.D. of three independent experiments carried out in triplicate. * p < 0.05; ** p < 0.01; *** p < 0.001 vs. control.

2.6. Pigmentation of SK-MEL 188 Cells Sensitizes Them to the Effects of the New Vitamin D Analogs

SK-MEL188 melanoma cells grown in F10 medium did not produce visible pigmentation, but changing in concentration of tyrosine in medium from 11 to 217 µM stimulated pigmentation. This effect was obtained by mixing DMEM and F10 (50:50, v/v).

Previous studies have indicated that pigmentation can impair both the metabolism and activity of classical vitamin D derivatives in human melanomas [51–53]. However, in the case of some vitamin analogs, such as 21(OH)pD [54], pigment producing SKMEL 188 cells are more sensitive to treatment. Therefore, we evaluated the responsiveness of pigmented SK-MEL 188 cells (subclone of SK-MEL 188 with no VDR expression) to new vitamin D analogs.

Interestingly, the pigmented SK-MEL188b cells were significantly sensitized to the new vitamin D analogs (Figure 7) as compared with non-pigmented cells (Figure 5). IC50 values ranged from 0.04 nM for PRI-1732 to approximately 0.0004 nM, with the strongest effect being seen for PRI-1731 (Table 3).

Table 3. Summary of IC50 values for the inhibition of proliferation of pigmented human malignant melanoma SK-MEL 188 cells.

| Compound         | IC50 (nM) |
|------------------|-----------|
| 1,25(OH)2D3      | 0.0087    |
| 1,25(OH)2D2      | 0.0158    |
| PRI-1730         | 0.0011    |
| PRI-1731         | 0.0004    |
| PRI-1732         | 0.0380    |
| PRI-1733         | 0.0020    |
| PRI-1734         | 0.0054    |
Figure 7. The effect of Vitamin D analogs on the proliferation of pigmented human malignant melanoma SK-MEL 188b cells. The cells were treated with serial dilutions ($10^{-12}$–$10^{-6}$ M) of 1,25(OH)$_2$D$_3$ (A), 1,25(OH)$_2$D$_2$ (B), PRI-1730—PRI-1734 (panels (C–G), respectively) for 24 h. Data shown are the mean from three independent experiments ± S.D. Statistical significance was estimated using One–Way ANOVA and presented as * $p < 0.05$, ** $p < 0.005$, *** $p < 0.0005$ vs. control.

2.7. Pigmentation of SK-MEL 188b Cells Affected Cell Cycle Distribution of Melanoma Cells after Treatment with Vitamin D Analogs

When analogs were tested at 100 nM against pigmented SK-MEL 188b melanoma cells there was no effect on the distribution of cells in the various phases of cell cycle (Figure 8A). Increasing the
concentration of vitamin D analogs to 1000 nM resulted in an effect similar to that observed previously for A375 cells, as to an increase in the percentage of melanoma cells in the G0/G1 phases of cell cycle (Figure 8B).

**Figure 8.** Effect of 24 h incubation with vitamin D analogs at 100 nM (A) and 1000 nM (B) concentration on the distribution of pigmented human malignant melanoma SK-MEL 188 cells throughout the phases of cell cycle. Cells were harvested, stained with propidium iodide and analyzed by Flow Cytometry. Data presented are the mean ± S.D. of three independent experiments carried out in triplicate. *p < 0.05 vs. control.

3. Discussion

There is good evidence from experimental studies to support the development of vitamins D as an anticancer therapeutic [40,55]. In keeping, there is a strong correlation between an adequate level of 25(OH)D and a decreased incidence of many different malignancies, including melanoma [35–39,56]. However, there is a need to develop more effective vitamin D analogs.

Incubation of A375 melanoma cells with 1,25(OH)2D2 and 1,25(OH)2D3 for 24 h resulted in around a 10% decrease in the viability of cells (Figure 2). This inhibitory effect of 1,25(OH)2D3 on proliferation is consistent with previous reports [40,43,57]. Interestingly, human malignant melanoma A375 cells showed an increased sensitivity to our DPM analogs of 1,25(OH)2D2 as to inhibit proliferation of these cells required several times less 1,25(OH)2D3 than the amount of 1,25(OH)2D2 required. Quite unexpectedly, introducing 22-hydroxyl and saturation in the side-chain (Figure 9, modification 1) of 1,25(OH)2D2 led to a reduced activity as to the resulting analog PRI-1730 (Table 1, IC50 1.500 nM compared to 0.036 for 1,25(OH)2D2). A likely explanation is the addition of 22-hydroxyl, as the Δ22 unsaturation in the side-chain, has long been known [58] to not exert a substantial influence on activity. On the contrary, introducing 5,6-trans, i.e., (5Z,7Z) modification 2 into the structure of PRI-1730 gave the analog PRI-1732 that inhibited proliferation of A375 cells at 30-fold lower concentrations (IC50 0.053 compared to 1.500 for PRI-1730). However, this modification (4) was not effective when introduced as a single point modification (SPM) [59] in the structure of plain 1,25(OH)2D2 and led to a 15-fold reduction of the activity in the resulting analog. Further inversion of the absolute configuration at C-24 in PRI-1732 (modification 3) reduced the activity of the analog PRI-1734 10-fold (IC50 0.497 for PRI-1734 compared to 0.053 for PRI-1732). Interestingly, the same inversion (modification 5) in PRI-1731 into PRI-1733 increased the activity, (from an IC50 value of 0.524 to 0.028) indicating 5,6-trans modification exerts a dominating effect when the activity reducing 22-hydroxyl is absent. Finally, introducing 22-hydroxyl (modification 6) into the structure of 24-epi-5,6-trans analog PRI-1733 also reduced the activity, a in the case of modification 1. PRI-1734 was slightly more active than 1,25(OH)2D3 (IC50 for PRI-1734 0.497 and for 1,25(OH)2D3 0.656) and this effect appears to be specific for melanoma cells and PRI-1734 is inactive against the human promyelocytic leukemia cell line HL-60 [60].

The effect exerted on cell proliferation by our novel analogs was observed to be dependent on the presence of VDR in cells, as the SK-MEL 188b cells which lack VDR expression were largely
unresponsive to the analogs. Indeed, a lack of VDR has been reported to be a mechanism that underlies unresponsiveness of melanoma cells to the antiproliferative effects of vitamin D analogs, as reported by Seifert et al. in the case of the SK-MEL 5 cell line [61] (see also Szyszka et al. [40] for recent review). On the other hand, our data have shown that moderate pigmentation of SK-MEL 188b sensitizes them to the effect of vitamin D analogs (Figure 7). A similar finding has been reported from studies of murine melanoma cell lines [41], in which pigmentation increased the expression of VDR and CYP24A1 at the mRNA level, and of SK-MEL 188 human melanoma cells [54]. Interestingly, the analog PRI-1731 was the only one that significantly inhibited the proliferation of non-pigmented SK-MEL 188b melanoma cells. This analog exerted also the strongest effect against pigmented SK-MEL 188b cells, having an IC50 value of 0.0004 nM (Table 3).

Finally, it is important to emphasize that the new vitamin D2 analogs maybe an effective alternative to 1,25(OH)2D3 in the treatment of melanoma. Furthermore, the anti-proliferative activity of compounds investigated against pigmented melanoma cells is of special interest because pigmentation is usually associated with an enhanced drug resistance.

4. Materials and Methods

4.1. Vitamin D Analogs

1,25-Dihydroxyvitamin D2 and the analogs PRI-1730, PRI-1731, PRI-1732, PRI-1733 and PRI-1734 (Figure 9) were synthesized [62] at the Chemistry Department of the Pharmaceutical Research Institute, Warsaw, Poland. The compounds gave analytical data (1H and 13C NMR spectra, recorded on a Varian GEMINI-200, Varian S 500 and Varian S 600 spectrometers, Varian Medical Systems, Inc., Palo Alto, CA, USA; UV spectra, taken in ethanolic solutions on a Shimadzu UV-160A spectrophotometer, Shimadzu Corp., Kyoto, Japan; mass spectra (MS) and high-resolution MS (HRMS), recorded on a Maldi Spectrometer SYNAPT G2-S HDMS; Waters Corp., Milford, MA, USA) consistent with the assigned structures. Amber glass ampoules were filled with ethanolic solution of 50 µg of analogs and the solutions were dried down under a stream of argon and the ampoules flame sealed. The quantity of an analog in an ampoule was confirmed by UV.

Figure 9. Structures of analogs of 1,25-dihydroxyvitamin D2 (1,25(OH)2D2) and the modifications introduced. 1 and 6—introducing 22-hydroxyl and saturation in the side-chain, 2 and 4—introducing (5Z,7Z) modification, 3 and 5—inversion of the absolute configuration at C-24.
4.2. Cell Culture

Human malignant melanoma A375 cells and SK-MEL 188b (a spontaneous sub-clone of SK-MEL188 that does not expressing VDR) cells were cultured in DMEM (Sigma, Poznan, Poland) and Ham's F-10 media (Sigma), respectively, supplemented with 10% fetal bovine serum (Sigma) and 1% penicillin/streptomycin (Sigma). Charcoal-stripped fetal bovine serum was used in all experiments to examine the effects of vitamin D analogs.

Culturing SK-MEL 188b melanoma cells in a medium high in tyrosine induced a rapid production melanin [63] with attendant changes in the differentiation status of cells. The tyrosine concentration in the medium used, 50:50 DMEM:F-10, was 217 µM.

4.3. Proliferation Assay

To measure the effects of analogs on cell proliferation, cells were seeded in 96 well plates at a density 5000 cells per well and after 24 h were treated with serial dilutions of the compounds being tested for an additional 24 h. Following incubation cells were fixed with 10% trichloracetic acid (TCA, Sigma) for 1 h at 4 °C. Plates were washed five times with distilled water and air-dried. A staining solution comprising 0.4% SRB (sulphorhodamine B, Sigma) in acetic acid was added to each well and after 15 min. plates were washed with 1% acetic acid five times and air-dried. SRB dye was solubilized using a solution of 10 mM buffered Tris Base (pH 10.5). Absorbance was measured at 570 nm using an Epoch spectrophotometer (BioTek, Winooski, VT, USA).

4.4. Cell Cycle Analysis

The cell cycle status of treated cells was analyzed by quantification of DNA content. Cells were seeded in 6 well plates at a density 150,000 cells per well and after 24 h were treated with vitamin D analogs at 100–1000 nM concentration for an additional 24 h. After fixation of cells in 70% ethanol for 24–48 h at 4 °C, cells were treated with ribonuclease in order to removed RNA contamination and DNA was stained with propidium iodide (PI, Sigma). Fluorescence of the PI-stained cells was measured by flow cytometry (Ex 536 nm, Em 617 nm, FACSCalibur, Becton Dickinson, Franklin Lakes, NJ, USA). Results were analyzed by CellQuest Pro Software (Becton Dickinson) and expressed as a percentage of cells with a DNA content corresponding to apoptotic/necrotic cells (subG1 fraction) or cells in G1, S and G2/M phases of the cycle.

4.5. cDNA Preparation and PCR Assays

Total RNA was isolated by using the Total RNA MiniPLUS kit (A&A Biotechnology, Gdynia, Poland), following the manufacturer’s instructions. The RNA concentrations were determined using Epoch Microplate Spectrophotometer (BioTek, Winooski, VT, USA). RNA extracted was reverse transcribed and cDNA synthesized using RevertAid™ First Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA). Real Time PCR was performed using an StepOnePlus™ Real-Time PCR System (Life Technologies-Applied Biosystems, Grand Island, NY, USA) with Real Time HS 2x PCR Master Mix SYBR® kit (A&A Biotechnology). The primer sets (Table 4) used for PCR were designed by authors and have been published previously [42]. RPL-37A was used as a housekeeping gene. All primers were purchased from Sigma-Aldrich, Munich, Germany. The expression of the genes were normalized by comparative ΔΔ-Ct method, using RPL37A as a housekeeping gene, followed by calibration (fold change) to normalized expression data of samples from control (ratio = 1). To ensure specificity of the PCR amplification, dynamic melting curve analysis was performed for all reactions.
4.6. Statistical Analyses

Statistical analysis was performed using Microsoft Excel or GraphPad Prism v 6.03 (GraphPad Software, San Diego, CA, USA). Data were subjected to Student’s t-test (for two groups) or one-way analysis of variance and appropriate post hoc test (the ANOVA Kruskal–Wallis test for comparison of several groups). Data are expressed as mean ± S.D. Each experiment was repeated at least three times in triplicate. Differences are shown as significant at $p < 0.05$, $p < 0.01$ or $p < 0.001$, as indicated.

5. Conclusions

Many studies have reported that the biological activities of 1,25(OH)$_2$D$_2$ and 1,25(OH)$_2$D$_3$ are very similar [45]. By contrast, the human malignant melanoma cell lines A375 and SK-MEL 188b, investigated in this study responded differently to the treatment with 1,25(OH)$_2$D$_3$ and 1,25(OH)$_2$D$_2$. The response of SK-MEL 188b cells to a given analog was mostly similar to that of A375 cell line. As expected, 5,6-trans modification was found to be advantageous to activity, but not as a single point modification, as in the case of the formal conversion of 1,25(OH)$_2$D$_2$ into the analog PRI-1731. The influence of adding 22-hydroxyl in the side-chain was first evaluated. Surprisingly, this modification significantly reduced the activity of analogs as to both the natural and 5,6-trans series. As such, this modification might be useful when designing a vitamin D antagonist. The activities of analogs of 1,25(OH)$_2$D$_2$ were variable as to the cell line tested. PRI-1734 showed very low activity, as compared to 1,25(OH)$_2$D$_2$, when tested against A375 cells and SK-MEL 188b cells [60]. However, PRI-1734 it was still more active than 1,25(OH)$_2$D$_3$ against A375 cells.

The IC$_{50}$ obtained for 1,25(OH)$_2$D$_2$ for inhibition of proliferation of A375 cells and SK-MEL 188b was several fold lower than that of 1,25(OH)$_2$D$_3$. This supports the viewpoint that analogs of 1,25(OH)$_2$D$_2$ may be a good alternative to 1,25(OH)$_2$D$_3$ and its analogs as to developing anticancer therapeutics. In this regard, it will be important to investigate whether the substantial differences observed for the activities of 1,25(OH)$_2$D$_2$ and 1,25(OH)$_2$D$_3$ against the human malignant melanoma cell lines A375 and SK-MEL 188b applies to other malignant cell lines.

Acknowledgments: The research leading to these results has received funding also from the People Program (Marie Curie Actions) of the European Union’s Seventh Framework Program FP7/2007–2013 under Research Executive Agency grant agreement No. 315902. The author (SN) gratefully acknowledges receipt of a Marie Curie Research Associate post. GB and AK are partners within the Marie Curie Initial Training Network DECIDE (Decision-making within cells and differentiation entities therapies). This work was presented in part by SN as a poster at the 18th Workshop on Vitamin D, in Delft, The Netherlands, 21–24 April 2015 and as a short talk at the 2nd International Conference Vitamin D—Maximum, Minimum, Optimum, Warsaw, Poland, 16–17 October 2015.

Author Contributions: Andrzej Kutner initiated the study, Anna Piotrowska carried out the experiments except for RNA isolation, analyzed the data and contributed to writing of the manuscript, Justyna Wierzbicka isolated RNA, Sharmin Nadkarni, Andrzej Kutner and Geoffrey Brown analyzed and discussed the data and contributed to the writing of the manuscript, Michał A. Żmijewski supervised the study, analyzed the data and contributed to writing of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
1,25(OH)\(_2\)D\(_2\) — 1,25-dihydroxyvitamin D\(_2\); 1,25(OH)\(_2\)D\(_3\) — 1,25-dihydroxyvitamin D\(_3\) (calcitriol); 25(OH)D — 25-hydroxyvitamin D; 7-DHC — 7-dehydrocholesterol (provitamin D\(_3\), cholesta-5,7-dien-3\(\beta\)-ol); ATRA — All-trans retinoic acid; D\(_2\) — ergocalciferol; D\(_3\) — cholecalciferol; DPM — double point modified (analogs); HRMS — high-resolution mass spectrometry; M — mole, unit; NMR — nuclear magnetic resonance; ns — not significant; NT — not treated; SPM — single point modified (analogs); UVA/B — ultraviolet radiation A and B; VDR — vitamin D receptor; VDRE — vitamin D response elements.

References
1. Bikle, D.D. Vitamin d: An ancient hormone. *Exp. Dermatol.* 2011, 20, 7–13. [CrossRef] [PubMed]
2. Wierzbicka, J.; Piotrowska, A.; Zmijewski, M.A. The renaissance of vitamin D. *Acta Biochim. Pol.* 2014, 61, 679–686. [PubMed]
3. Wacker, M.; Holick, M.F. Sunlight and vitamin D: A global perspective for health. *Derm. Endocrinol.* 2013, 5, 51–108. [CrossRef] [PubMed]
4. Bikle, D.D. Vitamin D metabolism, mechanism of action, and clinical applications. *Chem. Biol.* 2014, 21, 319–329. [CrossRef] [PubMed]
5. Holick, M.F.; Biancuzzo, R.M.; Chen, T.C.; Young, A.; Bibulb, D.; Reitz, R.; Salameh, W.; Ameri, A.; Tannenbaum, A.D. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. *J. Clin. Endocrinol. Metab.* 2008, 93, 677–681. [CrossRef] [PubMed]
6. Alshahrani, F.; Aljohani, N. Vitamin D: Deficiency, sufficiency and toxicity. *Nutrients* 2013, 5, 3605–3616. [CrossRef] [PubMed]
7. Grober, U.; Spitz, J.; Reichrath, J.; Kisters, K.; Holick, M.F. Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcare. *Derm. Endocrinol.* 2013, 5, 331–347. [CrossRef] [PubMed]
8. Adams, J.S.; Hewison, M. Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. *Arch. Biochem. Biophys.* 2012, 523, 95–102. [CrossRef] [PubMed]
9. Bikle, D.D. Vitamin D and the skin: Physiology and pathophysiology. *Rev. Endocr. Metab. Disord.* 2012, 13, 3–19. [CrossRef] [PubMed]
10. DeLuca, H.F. Overview of general physiologic features and functions of vitamin d. *Am. J. Clin. Nutr.* 2004, 80, 1689–1696.
11. Mason, R.S.; Sequeira, V.B.; Gordon-Thomson, C. Vitamin D: The light side of sunshine. *Eur. J. Clin. Nutr.* 2011, 65, 986–993. [CrossRef] [PubMed]
12. Mason, R.S. Vitamin D: A hormone for all seasons. *Climacteric* 2011, 14, 197–203. [CrossRef] [PubMed]
13. Pike, J.W.; Zella, L.A.; Meyer, M.B.; Fretz, J.A.; Kim, S. Molecular actions of 1,25-dihydroxyvitamin D3 on genes involved in calcium homeostasis. *J. Bone Miner. Res.* 2007, 22, 16–19. [CrossRef] [PubMed]
14. Haussler, M.R.; Jurutka, P.W.; Mizwicki, M.; Norman, A.W. Vitamin D receptor (vdr)-mediated actions of 1\(\alpha\),25(OH)\(_2\) vitamin D\(_3\): Genomic and non-genomic mechanisms. *Best Pract. Res. Clin. Endocrinol. Metab.* 2011, 25, 543–559. [CrossRef] [PubMed]
15. Haussler, M.R.; Whitfield, G.K.; Kaneko, I.; Haussler, C.A.; Hsieh, D.; Hsieh, J.C.; Jurutka, P.W. Molecular mechanisms of vitamin D action. *Calcif. Tissue Int.* 2013, 92, 77–98. [CrossRef] [PubMed]
16. Saccone, D.; Asani, F.; Bornman, L. Regulation of the vitamin D receptor gene by environment, genetics and epigenetics. *Gene* 2015, 561, 171–180. [CrossRef] [PubMed]
17. Pike, J.W.; Meyer, M.B. The vitamin D receptor: New paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D\(_3\). In *Endocrinology and Metabolism Clinics of North America*; 2010 Elsevier Inc.: Philadelphia, PA, USA, 2010; Volume 39, pp. 255–269, table of contents.
18. Holick, M.F. Resurrection of vitamin D deficiency and rickets. *J. Clin. Investig.* 2006, 116, 2062–2072. [CrossRef] [PubMed]
19. Samuel, S.; Sitrin, M.D. Vitamin D’s role in cell proliferation and differentiation. *Nutr. Rev.* 2008, 66, 116–124. [CrossRef] [PubMed]
20. Bikle, D.D. Vitamin D regulated keratinocyte differentiation. *J. Cell. Biochem.* 2004, 92, 436–444. [CrossRef] [PubMed]
21. Bikle, D.D.; Oda, Y.; Xie, Z. Calcium and 1,25(OH)2D: Interacting drivers of epidermal differentiation. *J. Steroid Biochem. Mol. Biol.* 2004, 89, 355–360. [CrossRef] [PubMed]

22. Diaz, L.; Diaz-Munoz, M.; Garcia-Gaytan, A.C.; Mendez, I. Mechanistic effects of calcitriol in cancer biology. *Nutrients* 2015, 7, 5020–5050. [CrossRef] [PubMed]

23. Kubis, A.M.; Piwowar, A. The new insight on the regulatory role of the vitamin D3 in metabolic pathways characteristic for cancerogenesis and neurodegenerative diseases. *Ageing Res. Rev.* 2015, 24, 126–137. [CrossRef] [PubMed]

24. Sergeev, I.N. Vitamin D-mediated apoptosis in cancer and obesity. *Horm. Mol. Biol. Clin. Investig.* 2014, 20, 43–49. [CrossRef] [PubMed]

25. Holick, M.F. Vitamin D: A D-lightful solution for health. *J. Investig. Med.* 2011, 59, 872–880. [CrossRef] [PubMed]

26. Holick, M.F. Vitamin D: A D-lightful solution for good health. *J. Med. Biochem.* 2012, 31, 263–264. [CrossRef] [PubMed]

27. Ma, Y.; Trump, D.L.; Johnson, C.S. Vitamin D in combination cancer treatment. *J. Cancer* 2010, 1, 101–107. [CrossRef] [PubMed]

28. Ness, R.A.; Miller, D.D.; Li, W. The role of vitamin D in cancer prevention. *Chin. J. Nat. Med.* 2015, 13, 481–497. [CrossRef] [PubMed]

29. Krishnan, A.V.; Swami, S.; Feldman, D. Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: Importance of mammary cyp27b1 for treatment and prevention. *J. Steroid Biochem. Mol. Biol.* 2013, 136, 289–295. [CrossRef] [PubMed]

30. Morris, H.A. Vitamin D activities for health outcomes. *Ann. Lab. Med.* 2014, 34, 181–186. [CrossRef] [PubMed]

31. Mitchell, D. The relationship between vitamin D and cancer. *Clin. J. Oncol. Nurs.* 2011, 15, 557–560. [CrossRef] [PubMed]

32. Walentowicz-Sadlecka, M.; Sadlecki, P.; Walentowicz, P.; Grabiec, M. The role of vitamin D in the carcinogenesis of breast and ovarian cancer. *Ginekol. Pol.* 2013, 84, 305–308. [PubMed]

33. Schwartz, G.G. Vitamin D and intervention trials in prostate cancer: From theory to therapy. *Ann. Epidemiol.* 2009, 19, 96–102. [CrossRef] [PubMed]

34. Yin, L.; Ordonez-Mena, J.M.; Chen, T.; Schottker, B.; Arndt, V.; Brenner, H. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: A systematic review and meta-analysis. *Prev. Med.* 2013, 57, 753–764. [CrossRef] [PubMed]

35. Welsh, J.; Wietzke, J.A.; Zinser, G.M.; Byrne, B.; Smith, K.; Narvaez, C.J. Vitamin D-3 receptor as a target for breast cancer prevention. *J. Nutr.* 2003, 133, 242S–243S. [PubMed]

36. Mehta, R.G.; Hussain, E.A.; Mehta, R.R.; Das Gupta, T.K. Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of vitamin D. *Mutat. Res.* 2003, 523, 253–264. [CrossRef] [PubMed]

37. Lamprecht, S.A.; Lipkin, M. Chemoprevention of colon cancer by calcium, vitamin D and folate: Molecular mechanisms. *Nat. Rev. Cancer* 2003, 3, 601–614. [CrossRef] [PubMed]

38. Nakagawa, K.; Kawaura, A.; Kato, S.; Takeda, E.; Okano, T. 1α,25-dihydroxyvitamin d(3) is a preventive factor in the metastasis of lung cancer. *Carcinogenesis* 2005, 26, 429–440. [CrossRef] [PubMed]

39. Krishnan, A.V.; Peehl, D.M.; Feldman, D. The role of vitamin D in prostate cancer. *Recent Results Cancer Res.* 2003, 164, 205–221. [PubMed]

40. Szyszka, P.; Zmijewski, M.A.; Slominski, A.T. New vitamin D analogs as potential therapeutics in melanoma. *Expert Rev. Anticancer Ther.* 2012, 12, 585–599. [CrossRef] [PubMed]

41. Wasiewicz, T.; Szyszka, P.; Cichorek, M.; Janjetovic, Z.; Tuckey, R.C.; Slominski, A.T.; Zmijewski, M.A. Antitumor effects of vitamin D analogs on hamster and mouse melanoma cell lines in relation to melanin pigmentation. *Int. J. Mol. Sci.* 2015, 16, 6645–6667. [CrossRef] [PubMed]

42. Wierzbicka, J.M.; Binek, A.; Ahrends, T.; Nowacka, J.D.; Szydlowska, A.; Turczyk, L.; Wąsiewicz, T.; Wierzbicki, P.M.; Sałej, R.; Tuckey, R.C.; *et al.* Differential antitumor effects of vitamin D analogues on colorectal carcinoma in culture. *Int. J. Oncol.* 2015, 47, 1084–1096. [CrossRef] [PubMed]

43. Slominski, A.; Kim, T.K.; Zmijewski, M.A.; Janjetovic, Z.; Li, W.; Chen, J.; Kusniatsova, E.I.; Semak, I.; Postlethwaite, A.; Miller, D.D.; *et al.* Novel vitamin D photoproducts and their precursors in the skin. *Derm. Endocrinol.* 2013, 5, 7–19. [CrossRef] [PubMed]
44. Kotlarz, A.; Przybyszewska, M.; Swoboda, P.; Miloszewska, J.; Grygorowicz, M.A.; Kutner, A.; Markowicz, S. Differential interference of vitamin D analogs PRI-1906, PRI-2191, and PRI-2205 with the renewal of human colon cancer cells refractory to treatment with 5-fluorouracil. *Tumour Biol.* 2015. [CrossRef] [PubMed]

45. Trynda, J.; Turlej, E.; Milczarek, M.; Pietraszek, A.; Chodynski, M.; Kutner, A.; Wietrzyk, J. Antiiproliferative activity and *in vivo* toxicity of double-point modified analogs of 1,25-dihydroxyergocalciferol. *Int. J. Mol. Sci.* 2015, 16, 24873–24894. [CrossRef] [PubMed]

46. Huet, T.; Laverny, G.; Ciesielski, F.; Molnar, F.; Ramamoorthy, T.G.; Belorussova, A.Y.; Antony, P.; Potier, N.; Metzger, D.; Moras, D.; et al. A vitamin D receptor selectively activated by gemini analogs reveals ligand dependent and independent effects. *Cell Rep.* 2015, 10, 516–526. [CrossRef] [PubMed]

47. Malinska, M.; Kutner, A.; Wozniak, K. Predicted structures of new vitamin D receptor agonists based on available x-ray structures. *Steroids* 2015, 104, 220–229. [CrossRef] [PubMed]

48. Pietraszek, A.; Malinska, M.; Chodynski, M.; Krupa, M.; Krajewski, K.; Cmoch, P.; Wozniak, K.; Kutner, A. Synthesis and crystallographic study of 1,25-dihydroxyergocalciferol analogs. *Steroids* 2013, 78, 1003–1014. [CrossRef] [PubMed]

49. Nachliely, M.; Sharony, E.; Kutner, A.; Danilenko, M. Novel analogs of 1,25-dihydroxyvitamin D combined with a plant polyphenol as highly efficient inducers of differentiation in human acute myeloid leukemia cells. *J. Steroid Biochem. Mol. Biol.* 2015. [CrossRef] [PubMed]

50. Bolla, N.R.; Corcoran, A.; Yasuda, K.; Chodynski, M.; Krajewski, K.; Cmoch, P.; Marcinkowska, E.; Brown, G.; Sakaki, T.; Kutner, A. Synthesis and evaluation of geometric analogs of 1α,25-dihydroxyvitamin D2 as potential therapeutics. *J. Steroid Biochem. Mol. Biol.* 2015. [CrossRef] [PubMed]

51. Janjetovic, Z.; Brozyna, A.A.; Jozwicki, W.; Slominski, A.T. High basal NF-κB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives. *Br. J. Cancer* 2015, 105, 1874–1884. [CrossRef] [PubMed]

52. Brozyna, A.A.; Jozwicki, W.; Janjetovic, Z.; Slominski, A.T. Decreased vdr expression in cutaneous melanomas as marker of tumor progression: New data and analyses. *Anticancer Res.* 2014, 34, 2735–2743. [PubMed]

53. Ingraham, B.A.; Bragdon, B.; Nohe, A. Molecular basis of the potential of vitamin D to prevent cancer. *Curr. Med. Res. Opin.* 2008, 24, 139–149. [CrossRef] [PubMed]

54. Slominski, A.T.; Zmijewski, M.A.; Semak, I.; Zbytek, B.; Pisarchik, A.; Li, W.; Zjawiony, J.; Tuckey, R.C.; Kim, T.K.; Nguyen, M.N.; Jozwicki, W.; Pfeffer, S.R.; Pfeffer, L.M.; Sweatman, T.W.; Miller, D.D.; Smolen, A.T. High basal NF-κB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives. *J. Steroid Biochem. Mol. Biol.* 2015. [CrossRef] [PubMed]

55. Perlman, K.; Kutner, A.; Prahl, J.; Smith, C.; Inaba, M.; Schnoes, H.K.; DeLuca, H.F. 24-homologated 1,25-dihydroxyvitamin D3 compounds: Separation of calcium and cell differentiation activities. *Biochemistry* 1990, 29, 190–196. [PubMed]

56. Corcoran, A.; Bermudez, M.A.; Seoane, S.; Perez-Fernandez, R.; Krupa, M.; Pietraszek, A.; Chodynski, M.; Kutner, A.; Brown, G.; Marcinkowska, E. Biological evaluation of new vitamin D2 analogues. *J. Steroid Biochem. Mol. Biol.* 2015. [CrossRef] [PubMed]

57. Seifert, M.; Rech, M.; Meineke, V.; Tilgen, W.; Reichrath, J. Differential biological effects of 1,25-dihydroxyvitamin D3 on melanoma cell lines *in vitro*. *J. Steroid Biochem. Mol. Biol.* 2004, 89, 375–379. [CrossRef] [PubMed]
62. Nadkarni, S.; Chodynski, M.; Krajewski, K.; Cmoch, P.; Marcinkowska, E.; Brown, G.; Kutner, A. Convergent synthesis of double point modified analogs of 1α,25-dihydroxyvitamin D2 for biological evaluation. *J. Steroid Biochem. Mol. Biol.* 2015. [CrossRef] [PubMed]

63. Brozyna, A.A.; VanMiddlesworth, L.; Slominski, A.T. Inhibition of melanogenesis as a radiation sensitizer for melanoma therapy. *Int. J. Cancer* 2008, 123, 1448–1456. [CrossRef] [PubMed]